	US 12,084,482 B2
	Fusion proteins of natural human protein fragments to create orderly multimerized immunoglobulin Fc compositions
David S. Block, Baltimore, MD (US); and Henrik Olsen, Baltimore, MD (US)
Assigned to Gliknik Inc., Baltimore, MD (US)
Filed by Gliknik Inc., Baltimore, MD (US)
Filed on Aug. 12, 2021, as Appl. No. 17/400,367.
Application 17/400,367 is a division of application No. 15/642,175, filed on Jul. 5, 2017, granted, now 11,117,940.
Application 15/642,175 is a division of application No. 13/812,269, abandoned, previously published as PCT/US2011/045768, filed on Jul. 28, 2011.
Claims priority of provisional application 61/368,465, filed on Jul. 28, 2010.
Prior Publication US 2022/0056087 A1, Feb. 24, 2022
Int. Cl. A61K 39/395 (2006.01); A61K 31/573 (2006.01); A61K 45/06 (2006.01); A61P 37/00 (2006.01); C07K 14/47 (2006.01); C07K 16/00 (2006.01); A61K 39/00 (2006.01)

CPC C07K 14/47 (2013.01) [A61K 31/573 (2013.01); A61K 39/395 (2013.01); A61K 45/06 (2013.01); A61P 37/00 (2018.01); C07K 16/00 (2013.01); A61K 2039/505 (2013.01); C07K 2317/35 (2013.01); C07K 2317/52 (2013.01); C07K 2317/92 (2013.01); C07K 2319/30 (2013.01); C07K 2319/73 (2013.01); C07K 2319/735 (2013.01)]

15 Claims

1. A method of treating an inflammatory disease or autoimmune disease in a subject in need thereof comprising administering to the subject an effective amount of a pharmaceutical composition comprising a multimerized compound comprising two or more homodimeric stradomer units,

wherein each homodimeric stradomer unit comprises two stradomer unit monomers, and

wherein each stradomer unit monomer comprises amino acid residues 21-264 of SEQ ID NO:4.